Official global newsroom account for Biogen, a leading biotech company pioneering innovative science since 1978. Community guidelines: bit.ly/1MZocKs
Cambridge, MA
- Tweets 6,008
- Following 240
- Followers 44,758
- Likes 1,232
#News: Today, the Clinical Journal of the American Society of Nephrology published results from a Phase 3 analysis in adolescents with C3G and primary IC-MPGN. Read more: bit.ly/476pxiU
1
1
3
988
We’re heading to New Orleans for #PsychCongress2026! Together with Supernus Pharmaceuticals, we’ll share the latest real-world evidence in postpartum depression (PPD).
Attending? Connect with our team and visit us at booth 1041. Learn more: spr.ly/6016BGHj4y
1
2
910
At #EEC2026 we’re sharing the latest data from our investigational study for Dravet syndrome, exploring the disease’s underlying genetic cause. Stop by booth #38 and join us at our medical symposium to learn more about our work in this genetic and highly burdensome disease.
1
2
6
793
#News: We announced the completion of the acquisition of RayThera Inc. This acquisition marks another step in growing Biogen’s immunology portfolio, adding multiple potential assets for immune-mediated diseases. Read more: spr.ly/6012B1Dlmq
3
3
9
2,007
We’re attending #GlomConHawaii to share more about our approach to C3G and primary IC-MPGN. Stop by booth #25 to learn how Biogen is working to transform care in complement-driven and immune-mediated kidney diseases.
1
4
1,148
Today, we reported our Q2 results, demonstrating progress toward our goal of sustainable revenue growth. Read more: bit.ly/4yNFlUk
Forward-looking statements: biogen.com/forward-looking-s…
#Earnings $BIIB
2
934
#News: Today @synapticure announced its new ataxia care program. We’re proud to help support important awareness efforts as a part of our commitment to the broader ataxia communities. Read more: bit.ly/4vwPwtC
3
7
1,345
#News: Together with Eisai, we announced that the FDA has approved a new delivery option for people living with early Alzheimer’s disease. Learn more: bit.ly/4wGKCeL
1
8
1,008
#News: We’re attending the @alzassociation’s International Conference (#AAIC26) to share new data from our Alzheimer’s disease portfolio—including initial data from the Phase 2 study of our investigational tau-targeting therapy. Learn more: bit.ly/4eyKc3U
1
9
1,514
We’re in San Diego this week at #BIO2026 and look forward to connecting with biotech leaders from across the globe who share our ambition to deliver medicines to help transform patients’ lives. Learn about our partnering opportunities around the world: bit.ly/4gudEJC
1
2
4
1,067
At the @ATCMeeting, we're sharing new data on our investigational therapy designed to target CD-38 cells in antibody-mediated rejection. Join us to learn about our ongoing research in kidney transplantation and our late-stage clinical trials. Learn more: ow.ly/MNtN50ZcR2t
1
1
4
631
#News: Today, we announced an agreement to acquire RayThera Inc. With this deal, we aim to add multiple immunology assets to our portfolio that will contribute to our long-term pipeline potential. Read more about this deal: ow.ly/ogXF50Ze1H3
1
4
9
1,282
#News: Today, we announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for an investigational therapy for spinal muscular atrophy (SMA). Learn more about this important milestone: bit.ly/49B9vj0
1
4
16
1,364
